FREE PAPER

CALL FOR FREE PAPERS AND ABSTRACT SUBMISSION GUIDELINES

ABSTRACT SUBMISSION DEADLINE 15 APRIL 2027

To enhance the scientific value of the 12th Indonesian Pediatric Endocrinology Update (12th PEDENDO 2027) in conjunction with the APPES CME and APPES Fellow School, themed “From Early Detection to Lifelong Health: Practical & Equitable Pediatric Endocrine Care“, to be held on Thursday–Friday, 20–21 May 2027 at Merusaka Nusa Dua, Bali, we invite all participants to present their research and updates in the field of pediatric and adolescent endocrinology. Selected abstracts will be presented in Oral and E-Poster formats.

GENERAL REGULATION

  • All abstracts must be original work (Research Study or Case Report) in the field of pediatric and adolescent endocrinology.
  • The paper must not have been published prior to the 12th PEDENDO 2027.
  • Each primary Author may submit a maximum of 2 (two) abstracts.
  • Oral & E-Poster Presentations will be held on-site on 20–21 May 2027 at Merusaka Nusa Dua, Bali.
  • The presenter must be registered as a participant of the 12th PEDENDO 2027 On-Site Symposium.

HOW TO SUBMIT YOUR ABSTRACT (ONLINE)

  1. Register as a participant of 12th PEDENDO 2027 (On-site Symposium).
  2. Participants are encouraged to complete their registration before submitting their Abstracts.
  3. Submit your abstract as a Microsoft Word attachment via the “Abstract Submission” page (this page below).
  4. Complete all the presenter details as follows:
    • Presenter Name
    • Email address
    • Mobile Number (WhatsApp)
    • Institution
    • Abstract Title
    • Registration Number*

*) Participant Registration Number is provided on the registration notification (or invoice). The registration fee can be paid after the review process and the announcement of abstract acceptance.

Dot-3 Dot-3

ABSTRACT PREPARATION GUIDELINES
All Abstracts must be submitted online as a Microsoft Word .doc/.docx file, prepared as follows:

  1. Abstracts must be written in English; using Arial 11 pt font with single spacing
  2. Abstracts must not exceed 300 words, excluding the title and authors.
  3. The abstract title must be written in UPPER CASE (capital letters).
  4. Authors’ full name must be written with the first name followed by the family name, in upper and lower case.
  5. The primary author must be listed first, and the presenter’s name must be underlined.
  6. Affiliation details must be listed in the following order: department, institution/hospital, city/state, country.
  7. Avoid non-standard abbreviations, unfamiliar terms, symbols, or acronyms not easily understood by general readers. Non-standard abbreviations must be defined in full at first use.
  8. Use generic drug names, and express numbers as numerals.
  9. Abstracts must contain text only. Tables, graphs, and diagrams must NOT be included.
  10. References are not mandatory; if included, they count toward the word limit.
  11. Abstracts of research studies (including systematic reviews and meta-analyses) must consist of four paragraphs, as follows:
    • OBJECTIVE: State concisely why the study was conducted.
    • METHOD: Indicate the locale, sample number, principal test(s) performed, and the types of statistical analysis employed.
    • RESULT: Confirm or refute the hypothesis, supported by statistics where appropriate.
    • CONCLUSION: State the implications of the study for future patient management or for the understanding of basic processes.
  12. Case report abstracts are also accepted and must consist of three paragraphs, as follows:
    • OBJECTIVE: State concisely why this case is important to report, its novelty, and its clinical implications.
    • CASE: Description of the case.
    • CONCLUSION: A summary of the clinical implications of the case, suggestions for clinical application, precautions to be taken, or topics of further research required.

ABSTRACT ACKNOWLEDGEMENT

  • All abstracts will be reviewed by the Scientific Committee based on quality, clarity, relevance to the audience, and significance.
  • Letters of acceptance will be sent to the presenter’s email, together with the E-Poster Preparation Guidelines, no later than 25 April 2027. The E-Poster PDF must be submitted not later than 5 May 2027.
  • The E-Poster presentation schedule will be announced after the E-Poster PDF submission is complete.

WITHDRAWAL / CHANGES

  • Each abstract may be revised only once.
  • Revised abstracts must be emailed to freepaper@geoconvex.com with the subject “[12th PEDENDO 2027] Revised Abstract (Presenter Name)” no later than 15 April 2027.
  • Withdrawals or changes will not be accepted after this date.
  • Abstracts will be automatically cancelled if the registration payment is not completed by 15 May 2027.

PUBLICATION

  • The presenting author must be registered for the 12th PEDENDO 2027 On-site Symposium for the abstract to be included in the final program. Abstracts from presenters with incomplete registration will be disqualified and will not be published.
  • By submitting an abstract, authors agree to its publication in the official conference publications.
  • The Committee reserves the right to edit the abstract format for consistency in publication.

Abstract Submission Form

    IMPORTANT!

    Free Paper presenters must complete their registration for the 12th PEDENDO 2027 On-Site Symposium and obtain a registration number, as stated on the registration notification (or invoice).

    Registration payments not completed by 15 May 2027 will automatically disqualified of the Free Paper submission.

    The abstract file must be submitted in Microsoft Word format (.doc/.docx) with a maximum size of 5.0 MB. The upload process may take some time depending on internet speed and website traffic. Do not leave or close the page until the upload process is completed.